Thursday, July 28, 2011
A team at The Scripps Research Institute has
created a heroin vaccine
that, unlike conventional single-antigen vaccines, displays multiple drug-like
antigens. The vaccine led to robust antibody titers that blocked the effects of
heroin in rats, and the team now plans to evaluate the extent of vaccine
protection by giving animals escalating doses of heroin.1 As opposed
to current options for preventing heroin addiction, the new vaccine does not
carry a risk of abuse or diversion and should not raise compliance issues.
T. SciBX 4(29);
doi:10.1038/scibx.2011.815 Published online July 28, 2011
1. Stowe, G.N. et al.
J. Med. Chem.; published online June 21, 2011; doi:10.1021/jm200461m Contact:
Kim D. Janda, The Scripps Research Institute, La Jolla, Calif. e-mail: firstname.lastname@example.org
Celtic Pharmaceutical Holdings L.P., Hamilton, Bermuda
King's College London, London, U.K.
Nabi Biopharmaceuticals (NASDAQ:NABI), Rockville, Md.
National Institute on Drug Abuse, Bethesda, Md.
National Institutes of Health, Bethesda, Md.
The Scripps Research Institute, La Jolla, Calif.
Reed Army Institute of Research, Silver Spring, Md.